The objective of this study was to present two cases of adenosquamous cell carcinoma of the prostate following radiation therapy. Two patients with history of prostate cancer treated with radiation therapy presented with rectal bleeding and a large ulcerated rectal mass. The rectal biopsy revealed on both cases squamous cell carcinoma. The initial diagnosis was invasive squamous cell carcinoma from anal origin. Both patients underwent pelvic exenteration with continent urinary diversion. After extensive histological sampling and immunohistochemisty, they were correctly diagnosed of adenosquamous cell carcinoma of the prostate with invasion of the rectum. The patients died 6 and 16 months after surgery with widespread metastases. A review of the literature is presented. Adenosquamous cell carcinoma of the prostate is an unusual histological variant of prostate cancer. To our knowledge, only three cases of adenosquamous cell carcinoma of the prostate following radiation therapy have been reported. The unusual clinical and histopathological features of the two cases reported here led to an initial mistaken diagnosis. Adenosquamous cell carcinoma of the prostate should be considered in the differential diagnosis when a patient with prostate cancer develops a rectal mass or rectal bleeding following radiation therapy and the rectal biopsy reveals squamous cell carcinoma. Prostate Cancer and Prostatic Diseases (2000) 3, 53±56.
Introduction
Primary squamous cell carcinoma (SCC) or adenosquamous cell carcinoma (ASCC) of the prostate are extremely rare. 1 ± 4 SCC or ASCC of the prostate following radiation therapy, 5 hormonal therapy 6 or both 7, 8 have rarely been documented. We are reporting two cases of adenosquamous cell carcinoma of the prostate that presented with rectal bleeding as the initial symptom. Both patients had received in the past external beam radiation therapy for localized prostate cancer. The clinical and pathologic ®ndings are presented, as well as a review of the literature.
Report of two cases Case I
A 65-y-old White male, underwent TURP in July 1988 secondary to bladder outlet obstructing symptoms. Histopathological evaluation demonstrated a poorly differentiated prostatic adenocarcinoma (Gleason's score 9).
Metastatic work-up, including bone scan and CT scan of the abdomen and pelvis, was negative. The patient underwent external beam radiation therapy without any complications. In August 1990, he presented with perineal pain and rectal bleeding. Physical examination revealed a large ulcerated rectal mass. A rectal biopsy was performed, which demonstrated squamous cell carcinoma, presumably from the anal canal. A CT scan revealed a large pelvic mass compressing the bladder and extending into the rectal wall. A transrectal needle biopsy of the prostate also revealed a well differentiated, keratinizing squamous cell carcinoma. Metastatic work-up at this time was also negative and serum PSA and PAP levels were within normal limits. In September 1990, the patient underwent a pelvic exenteration with end colostomy and continent urinary diversion.
Histological sections from the exenteration specimen revealed an adenosquamous carcinoma diffusely involving both prostatic lobes with extension to the seminal vesicles, periprostatic soft tissue, urinary bladder and rectal wall. Benign squamous metaplasia was not observed. The major component was a well to moderately differentiated squamous cell carcinoma with extensive keratin formation ( Figure 1A) . A second component with glandular formation was observed, which represented less than 10% of the tumor (Figure 2A ). These glandular elements appeared to contain one cell type epithelium with malignant cytological features, including large eosinophilic nucleoli. The carcinoma in®ltrated throughout the rectal mucosa, which became ulcerated and necrotic. The squamous tumor cells were not in continuity with the rectal or anal epithelium. The hypogastric, iliac and mesenteric lymph nodes were negative for metastases. The carcinoma had extended to the periprostatic and perirectal soft tissue resection margins. Although originally this tumor was thought to be a SCC from the anal canal, this should not contain any glandular elements. With this additional ®nding, the differential diagnosis included adenosquamous carcinoma from possible anal, rectal or prostatic origin. Immunohistochemical studies were conducted to elucidate the histogenesis of this tumor.
Immunostaining for cytokeratins of low molecular weight (CAM 5.2 mAb) and high molecular weight (AE3 and 34bE12 mAbs), prostatic speci®c antigen (PSA mAb) and prostatic acid phosphatase (PAP mAb) were performed by the ABC immunoperoxidase procedure. 9 While simple epithelium (colon) expresses only low molecular weight cytokeratins (CAM5.2 ), complex or strati®ed epithelium (transitional) expresses cytokeratins of low and high molecular weights (CAM5.2 and AE3). In contrast, squamous epithelium expresses only cytokeratins of high molecular weight (AE3). Prostatic epithelium is made of two cell types: the basal cells, which express only high molecular weight cytokeratin (34bE12 or keratin 903) and the secretory cells, which express low molecular weight cytokeratin (CAM5.2). In addition, prostatic epithelial secretory cells express PAP and PSA, the latter considered a fairly speci®c prostatic marker. Since most carcinomas retain the same immunophenotype as the epithelium from which they are derived, the expression of cytokeratin in a tumor con®rms its epithelial origin, while the molecular weight of the cytokeratins expressed in the tumor will provide information about its possible origin. Thus, SCC derived from the anal canal should be positive for AE3, negative for CAM5.2 (occasionally, some SCC can be CAM5.2 positive), PSA and PAP. Adenocarcinoma from the rectum should be positive for CAM5.2 and negative for AE3, PSA and PAP. Adenocarcinoma from the prostate should be positive for CAM5.2 and PSA. Also, because prostatic carcinomatous glands are devoid of basal cells, adenocarcinoma from the prostate lacks any immunoreactivity with 34bE12 mAb. This last feature is helpful in distinguishing true prostatic carcinoma from benign prostatic glands with atypia secondary to radiotherapy, which may mimic carcinoma.
The following immunostaining results were obtained: moderate immunoreactivity with CAM 5.2 mAb was observed on both squamous and glandular tumoral components. Strong immunoreactivity with AE3 was observed only on the squamous component ( Figure 1B) . The glandular tumoral elements were weakly immunoreactive with PSA mAb ( Figure 2B ). Both, the squamous and the glandular tumoral components were not immu- 
Case II
A 73-y-old White male diagnosed with a T1b, prostatic adenocarcinoma in 1988 (unknown Gleason's score), underwent staging lymphadenectomy, which was negative, followed by external beam radiation therapy. In 1991 he developed bladder outlet obstructive symptoms and underwent a TURP, which demonstrated a high-grade adenocarcinoma of the prostate (Gleason's score 8). Subsequently, he underwent bilateral orchiectomy. In March 1992, he developed mild hematuria and rectal bleeding. Physical examination revealed a large rectal mass with mucosal ulceration. A cystoscopy revealed radiation changes, post-TURP de®cit and no mucosal lesions. A rectal biopsy demonstrated squamous cell carcinoma. Metastatic work-up, including bone scan and CT scan of the abdomen and pelvis, was negative. PSA and PAP serum levels were within normal limits. He underwent pelvic exenteration, end colostomy and continent urinary diversion.
Histological sections from the exenteration specimen revealed a keratinizing moderately differentiated squamous cell carcinoma involving the bladder neck, trigone, right and left walls, as well as the perivesical fat. The tumor was predominantly a keratinizing squamous cell carcinoma ( Figure 3A) . However, minimal and focal glandular differentiation representing less than 5% of the tumor was observed ( Figure 3B ). Multiple histological sections failed to reveal benign squamous metaplasia. The carcinoma extended to the periurethral soft tissue resection margins. Sections from one lymph node isolated from the perivesical fat revealed extensive metastatic squamous cell carcinoma. Histological sections from the rectum revealed an unremarkable colonic mucosa and squamous cell carcinoma invading the rectal wall without mucosal involvement. The carcinoma had identical features as described in the urinary bladder. Sections from the perirectal lymph nodes were negative for metastasis.
The histopathological ®ndings were very similar to those described on the previous case, which leaded to the same differential diagnosis. Using the same rational as in case I, immunostaining for cytokeratins (CAM 5.2, AE3 and 34bE12 mAbs) and PSA and PAP mAbs were performed by the ABC immunoperoxidase procedure. 9 Strong immunoreactivity with AE3 mAb was observed in the squamous cell carcinoma component, which was negative for CAM5.2, PSA and PAP. Moderate immunoreactivity with CAM 5.2 and PSA mAbs was observed in the glandular elements, which were negative for PAP. Also, immunostaining for basal cells with 34bE12 mAb ( Figure 4A ) revealed negative results ( Figure 4B ). As in case I, the results of the immunostains con®rmed the diagnosis of adenosquamous carcinoma of prostatic origin.
In July 1992, the patient complained of abdominal pain, anorexia, and weight loss. MRI showed multiple liver metastases. He died in August 1992.
Discussion
Although benign squamous metaplasia of prostatic ducts is well documented, 10 SCC or ASCC are extremely rare. Wernert et al 11 described four types of SCC in the prostate: pure SCC, prostatic adenocarcinoma with malignant squamous cell component (ASCC) following hormonal therapy, urothelial carcinoma of the prostate with Adenosquamous cell carcinoma M Helal et al malignant squamous cell component, and transitional cell carcinoma of the urinary bladder with SCC differentiation invading the prostate. All of these types of SCC are very often associated with concomitant squamous metaplasia. The squamous cell carcinoma component is reported to be negative for PSA and PAP and positive for cytokeratin. A review of the literature has shown that nine of 11 patients with available survival data died between 1 and 17 months after diagnosis.
Saito 5 reported one case of ASCC of the prostate 4 y after radiation therapy for pure prostatic adenocarcinoma. The patient was treated by pelvic exenteration and radiation therapy for positive lateral margins; however, he expired 5 months later. Bennett et al 7 described a case of ASCC of the prostate following radiation and estrogen therapy. They hypothesized that the SCC component may have developed from squamous metaplasia following radiation and hormonal therapy. In support of this view, Devaney et al 6 reported a case of prostatic adenocarcinoma treated with diethylstilbestrol for 8 y, which then developed squamous metaplasia followed by ASCC. Myona 8 described a similar case presenting 10 y after the diagnosis of prostatic adenocarcinoma treated with radiation and hormonal therapy. He proposed that the SCC was derived from stem cells capable of multidirectional differentiation. As in all the cases previously reported, the SCC component was non-immunoreactive with PSA or PAP and immunoreactive with high molecular weight cytokeratin.
In our two cases, we were not able to document transition from squamous cell metaplasia to SCC after extensive histological sampling. Clinically, both patients presented with rectal bleeding and large ulcerated rectal masses. Rectal biopsy revealed SCC. However, when more extensive histological sampling after pelvic exenterations was done, this revealed ASCC invading the rectal wall on both patients. The squamous cell carcinoma component, as in the cases previously reported, was immunoreactive with cytokeratin of high molecular weight and non-immunoreactive with PSA or PAP. The glandular component of both tumors had the same immunophenotype as classical prostatic adenocarcinoma, being positive for PSA and low molecular weight cytokeratin. Since both patients were irradiated and radiation atypia can mimic carcinoma, one could argue whether these glandular elements were truly malignant. The malignant nature of these elements was supported not only by their architectural and cytological features but also by the lack of basal cells with 34bE12 mAb immunostaining. The ®nding of minimal but de®nite tumoral glandular differentiation with prostatic immunophenotype supports the prostatic origin of these tumors. Also, the complete lack of microscopic rectal mucosal involvement in one case and only focal involvement in the other as well as the lack of metastases to perirectal lymph nodes on both cases, militate against their possible origin from the anal canal. In spite of aggressive surgery, the disease progressed rapidly, and the patients expired with distant metastases.
In conclusion, postradiation ASCC of the prostate, although rare, does occur. This entity should be considered in the differential diagnosis when a patient with prostate cancer develops urinary retention or rectal or urethral bleeding following radiation therapy. In particular, it should be noted that the presentation of a rectal mass with characteristic SCC histological appearance can mislead pathologists if they are not aware of the clinical scenario. Furthermore, rectal biopsy might provide insuf®cient histological sampling to determine the origin of the tumor. The correlation of a positive history for prostate cancer treated with radiation therapy, followed by a rectal mass or rectal bleeding, which biopsy reveals as SCC ulcerating through but without continuity with the rectal mucosa, should suggest the possibility of ASCC of the prostate. A de®nitive diagnosis could be obtained only after extensive histopathological sampling and immunohistochemical techniques. As can be observed from the two cases reported and our review of the literature, this type of carcinoma has a very aggressive clinical course. Our two patients died with widespread metastases 6 and 16 months after their initial complaints.
